updates on the use of brentuximab vedotin in later-stage hl
Published 1 year ago • 120 plays • Length 1:04Download video MP4
Download video MP3
Similar videos
-
2:15
updates on the brentuximab vedotin for ctcl
-
3:09
real-world efficacy of brentuximab vedotin as consolidation therapy in patients with hl
-
1:24
novel agents for the treatment of hodgkin lymphoma: brentuximab vedotin and nivolumab
-
3:07
current indications for the use of brentuximab vedotin in hodgkin lymphoma
-
1:11
brentuximab vedotin: current status and future considerations for this agent in hl treatment
-
1:41
swog s1826: nivolumab avd vs brentuximab vedotin avd for advanced stage hodgkin lymphoma
-
2:39
an update on the cobra trial: pet-response adapted treatment with brentuximab vedotin for hl
-
5:25
asco 2023 highlights on nivolumab in advanced stage classic hodgkin lymphoma: the swog s1826 study
-
1:07:19
aug operations updates eng
-
2:44
cancer immunotherapy with nivolumab plus ipilimumab vs. chemotherapy: insights from checkmate 227
-
1:34:34
declaration of helsinki doh revision process
-
1:55
the real-world efficacy of brentuximab vedotin consolidation post-autosct in r/r hl
-
2:03
an updated analysis of echelon-1: 1l brentuximab vedotin chemotherapy in stage iii/iv classical hl
-
1:59
updates on the use of nivolumab in hodgkin lymphoma & how this agent may impact treatment
-
2:36
brentuximab vedotin versus pembrolizumab in r/r classical hodgkin lymphoma
-
1:02
seven-year os analysis from echelon-1: brentuximab vedotin avd versus abvd in hodgkin lymphoma
-
3:24
results from the breselibet trial of brentuximab vedotin chemotherapy for r/r hodgkin lymphoma
-
2:28
checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to allosct for hl
-
5:06
5-year follow-up of echelon-1: brentuximab plus avd versus abvd in hodgkin lymphoma
-
2:49
insights into the role of novel btkis in the treatment landscape of r/r cll
-
1:15
swog s1826: promising results with the combination of nivolumab-avd in hodgkin lymphoma
-
2:25
a final update of enhance: reflecting on the negative read-out of the study